Clinical trial · Interventional
CAR-T Cells in the Treatment of Malignant Hematological Tumors
Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor
NCT05619861CI-TRIAL-00062224unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, B-cell | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Leukemia, T-Cell | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Lymphoma, B-Cell | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CAR-T | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CAR-T
- description
- Autologous CAR-T cells, intravenous infusion, infusion dose 0.1-3 × 106CAR-T cells/kg
- interventionNames
- Biological: CAR-T
Primary outcomes (1)
- measure
- Safety: Incidence and severity of adverse events
- timeFrame
- 24 months post CAR-T cells infusion
- description
- The incidence and severity of adverse events and adverse reactions from infusion to withdrawal or before the safety follow-up period
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 70 Years
Show eligibility criteria text
1. With the consent of himself or the legal guardian and the signed informed consent, he is willing and able to comply with the planned visit, research and treatment, laboratory examination and other test procedures; Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor 2. Patients with recurrent and refractory hematopoiesis and lymphoid tissue tumors determined by clinical diagnosis; 3. Age 14-70 (including boundary value), both male and female; 4. Subjects with a physical status of 0\~2 in the American Eastern Oncology Collaboration Group (ECOG); 5. The results of treatment related antigens were positive; 6. The expected life span is more than 3 months from the date of signing the informed consent;
References
Publications (0)
Data not yet available
No reference posted for this study.